Intas-Accord to Acquire Prothya Biosolutions, Boosting Global Plasma Capacity

The deal, pending regulatory approvals, is expected to close soon, marking a key step for Intas and Accord in the plasma-derived medicinal products sector.

Intas Pharmaceuticals' subsidiary, Accord Plasma B.V,. has signed an agreement to acquire 100% ownership of Prothya Biosolutions Belgium BV and its subsidiaries. The deal, pending regulatory approvals and other customary closing conditions, is expected to finalize soon, marking a strategic move for Intas and Accord in the plasma-derived medicinal products (PDMP) sector.

Prothya Biosolutions, headquartered in Amsterdam and Brussels with plasma collection centers across Hungary, employs around 1,200 people. It is one of Europe’s largest plasma fractionators, formed in 2021 through the integration of Plasma Industries Belgium and Sanquin Plasma Products. The company combines over six decades of plasma collection and PDMP development experience.

Binish Chudgar, Chairman of Intas and Accord, said, "We are delighted to expand our plasma business by acquiring Prothya Biosolutions. Combined with our fractionation capabilities in India, this positions us to create a truly global plasma platform—serving patients worldwide with critical, often under-prescribed, therapies."

Intas's plasma division has supplied hospitals in India with PDMPs since 2015, with an annual fractionation capacity exceeding 1 million liters. The company also exports to multiple international markets, with plans to increase capacity at its Gujarat facility.

Nir Epstein, CEO of Prothya Biosolutions, noted, "Over the past four years, we've expanded into new markets, advanced critical therapies, established our own plasma collection network in Hungary, and supplied plasma derivatives to some of the world's leading PDMP companies—all while building a stronger, more resilient organization. I believe Accord is the right company to support Prothya and its people in the next phase of growth and global expansion."

The global PDMP market, including intravenous immunoglobulin (IVIG), is currently valued at $30 billion and is projected to reach $50 billion by 2035. This acquisition will enhance Intas's access to increased fractionation capacity and leverage Accord's commercial presence across 85 countries.

Financial advisory roles for this transaction are held by BofA Securities for Accord and Evercore for Prothya.

Stay tuned for more such updates on Digital Health News